HER2 biosensing through SPR-envelope tracking in plasmonic optical fiber gratings

被引:54
|
作者
Lobry, Maxime [1 ,5 ]
Loyez, Mederic [2 ]
Chah, Karima [1 ]
Hassan, Eman M. [3 ,4 ]
Goormaghtigh, Erik [5 ]
DeRosa, Maria C. [3 ]
Wattiez, Ruddy [2 ]
Caucheteur, Christophe [1 ]
机构
[1] Univ Mons, Electromagnetism & Telecommun Dept, 31 Bld Dolez, B-7000 Mons, Belgium
[2] Univ Mons, Prote & Microbiol Dept, 6 Av Champ Mars, B-7000 Mons, Belgium
[3] Carleton Univ, Inst Biochem, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada
[4] Natl Res Council Canada, Metrol Res Ctr, Ottawa, ON K1A 0R6, Canada
[5] Univ Libre Bruxelles, Ctr Struct Biol & Bioinformat, Lab Struct & Funct Biol Membranes, Bld Triomphe 2, B-1050 Brussels, Belgium
关键词
MODE RESONANCE; CLADDING-MODE; SENSORS; BREAST; BIOMARKER;
D O I
10.1364/BOE.401200
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In the biomedical detection context, plasmonic tilted fiber Bragg gratings (TFBGs) have been demonstrated to be a very accurate and sensitive sensing tool, especially well-adapted for biochemical detection. In this work, we have developed an aptasensor following a triple strategy to improve the overall sensing performances and robustness. Single polarization fiber (SPF) is used as biosensor substrate while the demodulation is based on tracking a peculiar feature of the lower envelope of the cladding mode resonances spectrum. This method is highly sensitive and yields wavelength shifts several tens of times higher than the ones reported so far based on the tracking of individual modes of the spectrum. An amplification of the response is further performed through a sandwich assay by the use of specific antibodies. These improvements have been achieved on a biosensor developed tbr the detection of the HER2 (Human Epidermal Growth Factor Receptor-2) protein, a relevant breast cancer biomarker. These advanced developments can be very interesting for point-of-care biomedical measurements in a convenient practical way. (C) 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
引用
收藏
页码:4862 / 4871
页数:10
相关论文
共 7 条
  • [1] Cascaded Bragg gratings in photonic crystal fiber for plasmonic cladding mode-based biosensing of HER2 protein
    Rusyakina, Olga
    Geernaert, Thomas
    Loyez, Mederic
    Lobry, Maxime
    Chah, Karima
    Mergo, Pawel
    Thienpont, Hugo
    Caucheteur, Christophe
    Berghmans, Francis
    Baghdasaryan, Tigran
    [J]. SENSORS AND ACTUATORS B-CHEMICAL, 2023, 382
  • [2] HER2 breast cancer biomarker detection using a sandwich optical fiber assay
    Loyez, Mederic
    Lobry, Maxime
    Hassan, Eman M.
    DeRosa, Maria C.
    Caucheteur, Christophe
    Wattiez, Ruddy
    [J]. TALANTA, 2021, 221
  • [3] Comparative study of optical fiber immunosensors based on traditional antibody or nanobody for detecting HER2
    Guo, Wanmei
    Yu, Yongsen
    Xin, Chao
    Jin, Guangyong
    [J]. TALANTA, 2024, 277
  • [4] Plasmonic optical fiber gratings based on few-layer Ta2C MXenes for refractive index sensing
    Liu, Runcheng
    Yang, Wen
    Lu, Jiajun
    Shafi, Muhammad
    Jiang, Mingshun
    Jiang, Shouzhen
    [J]. NANOTECHNOLOGY, 2023, 34 (09)
  • [5] SARS-CoV-2 spike protein detection through a plasmonic D-shaped plastic optical fiber aptasensor
    Cennamo, Nunzio
    Pasquardini, Laura
    Arcadio, Francesco
    Lunelli, Lorenzo
    Vanzetti, Lia
    Carafa, Vincenzo
    Altucci, Lucia
    Zeni, Luigi
    [J]. TALANTA, 2021, 233
  • [6] Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy
    Tsai, Y-S
    Shiau, A-L
    Chen, Y-F
    Tsai, H-T
    Tzai, T-S
    Wu, C-L
    [J]. CANCER GENE THERAPY, 2010, 17 (01) : 37 - 48
  • [7] Enhancement of antitumor activity of gammaretrovirus carrying IL-12 gene through genetic modification of envelope targeting HER2 receptor: a promising strategy for bladder cancer therapy
    Y-S Tsai
    A-L Shiau
    Y-F Chen
    H-T Tsai
    T-S Tzai
    C-L Wu
    [J]. Cancer Gene Therapy, 2010, 17 : 37 - 48